BE854270A - Medicament anti-tumeur a base de compose du type lysolecithine - Google Patents

Medicament anti-tumeur a base de compose du type lysolecithine

Info

Publication number
BE854270A
BE854270A BE177280A BE177280A BE854270A BE 854270 A BE854270 A BE 854270A BE 177280 A BE177280 A BE 177280A BE 177280 A BE177280 A BE 177280A BE 854270 A BE854270 A BE 854270A
Authority
BE
Belgium
Prior art keywords
lysolecithin
type compound
product based
medicinal product
tumor medicinal
Prior art date
Application number
BE177280A
Other languages
English (en)
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of BE854270A publication Critical patent/BE854270A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/10Phosphatides, e.g. lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BE177280A 1976-05-04 1977-05-04 Medicament anti-tumeur a base de compose du type lysolecithine BE854270A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2619686A DE2619686C2 (de) 1976-05-04 1976-05-04 Verwendung eines Lysolecithins zur Tumorbehandlung

Publications (1)

Publication Number Publication Date
BE854270A true BE854270A (fr) 1977-11-04

Family

ID=5977045

Family Applications (1)

Application Number Title Priority Date Filing Date
BE177280A BE854270A (fr) 1976-05-04 1977-05-04 Medicament anti-tumeur a base de compose du type lysolecithine

Country Status (15)

Country Link
JP (1) JPS52134027A (fr)
AU (1) AU517586B2 (fr)
BE (1) BE854270A (fr)
CA (1) CA1094455A (fr)
DE (1) DE2619686C2 (fr)
FR (1) FR2364656A1 (fr)
GB (1) GB1583661A (fr)
IE (1) IE44927B1 (fr)
IL (1) IL51988A (fr)
IT (1) IT1071329B (fr)
LU (1) LU77248A1 (fr)
NL (1) NL189672C (fr)
NZ (1) NZ183981A (fr)
SE (1) SE7705071L (fr)
ZA (1) ZA772649B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5396311A (en) * 1977-01-29 1978-08-23 Toyama Chem Co Ltd Anti-cander drugs containing lysolecithins
JPS5528955A (en) * 1978-08-24 1980-02-29 Toyama Chem Co Ltd Novel glycerophosphoric acid derivative, its salt, their preparation, and carcinostatic agent containing the same.
GB2046092B (en) 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4408052A (en) * 1980-02-27 1983-10-04 Takeda Chemical Industries, Ltd. Phospholipid carbamates
US4551532A (en) * 1980-05-08 1985-11-05 Takeda Chemical Industries, Ltd. Ethylene glycol derivatives having anti-protozoan, anti-fungal and anti-tumor activity
DE3164332D1 (en) * 1980-10-21 1984-07-26 Boehringer Mannheim Gmbh Phospholipids that contain sulphur, process for their preparation and medicines containing these compounds
JPS5772914A (en) 1980-10-22 1982-05-07 Takeda Chem Ind Ltd Antitumor agent
DE3265157D1 (en) * 1981-03-30 1985-09-12 Takeda Chemical Industries Ltd Ethyleneglycol derivatives, their production and use
DE3127503A1 (de) * 1981-07-11 1983-02-17 Boehringer Mannheim Gmbh, 6800 Mannheim Neue phospholipide, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3131524A1 (de) * 1981-08-08 1983-02-24 Röhm GmbH, 6100 Darmstadt Verfahren zur herstellung physiologischer effektoren
US4562179A (en) * 1982-04-19 1985-12-31 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, and pharmaceutical composition of the same
DE3239858A1 (de) * 1982-07-06 1984-01-12 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neue d-mannitderivate als ausgangsprodukte zur synthese von phospholipiden
DE3239817A1 (de) * 1982-07-06 1984-01-12 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neue glycerinderivate zur synthese von phospholipiden
EP0103877B1 (fr) * 1982-09-21 1987-01-07 Fujisawa Pharmaceutical Co., Ltd. Dérivés phosphatés, leur procédé de préparation et médicaments les contenant
US4710579A (en) * 1984-11-09 1987-12-01 Takeda Chemical Industries, Ltd. 2-(acetoacetyloxy)-3-(octadecyloxy)propyl-3-trimethylammoniopropyl phosphate or a pharmaceutically acceptable salt thereof
US4761404A (en) * 1985-07-01 1988-08-02 Merck & Co., Inc. Phospholipid analogs useful as PAF synthesis inhibitors
ATE41007T1 (de) * 1985-07-15 1989-03-15 Takeda Chemical Industries Ltd 2-alkanoyloxypropanderivate, ihre herstellung und verwendung.
JPS6294A (ja) * 1986-05-09 1987-01-06 Toyama Chem Co Ltd 新規なグリセロリン酸誘導体およびその塩並びにそれらの製造法
JP2561478B2 (ja) * 1986-07-22 1996-12-11 武田薬品工業株式会社 グリセリン誘導体
US5036152A (en) * 1988-03-10 1991-07-30 Hoechst-Roussel Pharmaceuticals Incorporated Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids
US4888328A (en) * 1988-03-10 1989-12-19 Hoeschst-Roussel Incorporated Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids
DE3906952A1 (de) * 1989-03-04 1990-09-06 Boehringer Mannheim Gmbh (3-(c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)6(pfeil abwaerts)-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)8(pfeil abwaerts))alkansulfinyl- und sulfonyl-2-methoxymethyl-propyl)-(2-trimethylammonio-ethyl) phosphate, verfahren zu deren herstellung diese verbindungen enthaltende arzneimittel
DE3918082A1 (de) * 1989-06-02 1991-01-24 Max Planck Gesellschaft Mittel gegen autoimmunerkrankungen
DE3935580C2 (de) * 1989-10-25 1998-05-28 Medmark Pharma Gmbh Verwendung eines pharmazeutischen Wirkstoffes zur Behandlung von HIV-Infektionen
EP0581793A1 (fr) * 1991-04-25 1994-02-09 University Of British Columbia Phosphonates et phosphinates utilises comme agents anticancereux, anti-inflammatoires, antiallergiques et anti-myocardites
ES2034885B1 (es) * 1991-07-10 1994-03-01 Menarini Lab Procedimiento para la preparacion de cetoalquilglicerofosfolipidos.
ATE198419T1 (de) * 1994-10-14 2001-01-15 Liposome Co Inc Etherlipid-liposomen und deren therapeutische verwendung
US5942246A (en) * 1996-02-16 1999-08-24 The Liposome Company, Inc. Etherlipid containing multiple lipid liposomes
US6667053B1 (en) 1996-02-16 2003-12-23 Elan Pharmaceuticals, Inc. D and L etherlipid stereoisomers and liposomes
US5965159A (en) * 1996-02-16 1999-10-12 The Liposome Company, Inc. Etherlipid-containing multiple lipid liposomes
USRE39042E1 (en) * 1996-02-16 2006-03-28 The Liposome Company, Inc. Etherlipid-containing multiple lipid liposomes
US6007839A (en) * 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
US6135426A (en) * 1998-01-07 2000-10-24 Briggs And Stratton Corporation Priming system for internal combustion engines
CN101610758A (zh) 2006-11-10 2009-12-23 阿尔法普托斯有限公司 含有三取代甘油化合物的口服剂型
US8324188B2 (en) 2006-11-10 2012-12-04 Vladimir Khazak Combinations of ET-18-O-CH3and anti-cancer agents for the treatment of cancer
ES2391226T3 (es) * 2006-12-20 2012-11-22 Alphaptose Gmbh Forma farmacéutica tópica que comprende compuestos de glicerol tri-sustituido
RU2474427C2 (ru) * 2006-12-20 2013-02-10 Универзитетсклиникум Хамбург-Эппендорф Применение тризамещенных соединений глицерина для лечения гематологических злокачественных опухолей
WO2013156630A1 (fr) 2012-04-20 2013-10-24 Alphaptose Gmbh Enantiomère s d'un composé glycérol tri-substitué

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2009341C3 (de) * 1970-02-27 1979-06-21 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen 3-Octadecyloxy-propanol-(l)-phosphorsäure-monocholinester und Verfahren zu dessen Herstellung
DE2009342C3 (de) * 1970-02-27 1980-12-18 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Glycerin-alkyläther-(l)-phosphorsäure-(3)-monocholinestern
DE2009343C3 (de) * 1970-02-27 1980-10-23 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Lysolecithinen als immunologische Adjuvantien
DE2033361C3 (de) * 1970-07-06 1980-02-21 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Acylpropandiol-(13)-phosphorsäurecholinester und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
IL51988A (en) 1981-05-20
LU77248A1 (fr) 1977-12-13
ZA772649B (en) 1978-04-26
NL189672B (nl) 1993-01-18
FR2364656B1 (fr) 1980-03-07
FR2364656A1 (fr) 1978-04-14
NL189672C (nl) 1993-06-16
AU2481977A (en) 1978-11-09
DE2619686A1 (de) 1977-11-24
SE7705071L (sv) 1977-11-05
CA1094455A (fr) 1981-01-27
AU517586B2 (en) 1981-08-13
IL51988A0 (en) 1977-07-31
JPS52134027A (en) 1977-11-09
IT1071329B (it) 1985-04-02
NZ183981A (en) 1980-04-28
NL7704723A (nl) 1977-11-08
IE44927B1 (en) 1982-05-19
DE2619686C2 (de) 1986-08-07
IE44927L (en) 1977-11-04
GB1583661A (en) 1981-01-28
JPS6146455B2 (fr) 1986-10-14

Similar Documents

Publication Publication Date Title
BE854270A (fr) Medicament anti-tumeur a base de compose du type lysolecithine
FR2304348A1 (fr) Medicament a base de sulfadiazine zincique
BE838938A (fr) Comprimes efferverscents d'edulcorants
SE7709359L (sv) Farmaceutisk doseringsform
BE854925A (fr) Acides 12-azaprostanoiques utiles comme medicament
BE883495A (fr) Medicament hypolipemiqude a base de carnitine
BE844532A (fr) Medicament a base d'un derive du benzothiadiazole
FR2307541A1 (fr) Medicament a base d'un polypeptide
FI763506A (fi) Farmaceutisk naeringsfoerpackning
BE862872A (fr) Medicament a base d'un compose heterocyclique bicyclique condense
FI773812A (fi) Farmaceutiska foereningar
JPS52128357A (en) Antiitumor drug
SE7705851L (sv) Forfarande for framstellning av en farmaceutisk komposition
JPS5296750A (en) Oral drug compound
FI773813A (fi) Farmaceutiska foereningar
JPS5325579A (en) Pharmaceutical compound
BE853569A (nl) Medicinale preparaten
FR2342067A1 (fr) Medicament a base d'un derive de la quinoleine
FR2347043A1 (fr) Medicament diuretique
BE811547A (fr) Medicament a base d'un derive de la 7h-benzocycloheptene-7-one
FR2337555A1 (fr) Medicament a base de 1,3-bis(2-tetrahydrofuryl)-5-fluoro-uracile
AU517608B2 (en) Medicaments
BE801014A (fr) Medicament a base d'(hydroxy-2 indanyl-2)1 propylamine
JPS5338620A (en) Isomalin antiimold drug
ZA777335B (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENS

Effective date: 19970504